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Abstract
Background: Targeted alpha therapy (TAT) offers advantages over current β-emitting conjugates for peptide
receptor radionuclide therapy (PRRT) of neuroendocrine tumors. PRRT with 177Lu-DOTATATE or 90Y-DOTATOC has
shown dose-limiting nephrotoxicity due to radiopeptide retention in the proximal tubules. Pharmacological
protection can reduce renal uptake of radiopeptides, e.g., positively charged amino acids, to saturate in the
proximal tubules, thereby enabling higher radioactivity to be safely administered. The aim of this preclinical study
was to evaluate the therapeutic effect of 213Bi-DOTATATE with and without renal protection using L-lysine in mice.
Tumor uptake and kinetics as a function of injected mass of peptide (range 0.03–3 nmol) were investigated using
111In-DOTATATE. These results allowed estimation of the mean radiation absorbed tumor dose for 213Bi-DOTATATE.
Pharmacokinetics and dosimetry of 213Bi-DOTATATE was determined in mice, in combination with renal protection.
A dose escalation study with 213Bi-DOTATATE was performed to determine the maximum tolerated dose (MTD)
with and without pre-administration of L-lysine as for renal protection. Neutrophil gelatinase-associated lipocalin
(NGAL) served as renal biomarker to determine kidney injury.
Results: The maximum mean radiation absorbed tumor dose occurred at 0.03 nmol and the minimum at 3 nmol.
Similar mean radiation absorbed tumor doses were determined for 0.1 and 0.3 nmol with a mean radiation absorbed
dose of approximately 0.5 Gy/MBq 213Bi-DOTATATE. The optimal mass of injected peptide was found to be 0.3 nmol.
Tumor uptake was similar for 111In-DOTATATE and 213Bi-DOTATATE at 0.3 nmol peptide. Lysine reduced the renal
uptake of 213Bi-DOTATATE by 50% with no effect on the tumor uptake. The MTD was <13.0 ± 1.6 MBq in absence of
L-lysine and 21.7 ± 1.9 MBq with L-lysine renal protection, both imparting an LD50 mean renal radiation absorbed dose
of 20 Gy. A correlation was found between the amount of injected radioactivity and NGAL levels.
Conclusions: The therapeutic potential of 213Bi-DOTATATE was illustrated by significantly decreased tumor burden and
improved overall survival. Renal protection with L-lysine immediately prior to TAT with 213Bi-DOTATATE prolonged
survival providing substantial evidence for pharmacological nephron blockade to mitigate nephrotoxicity.
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Background
Targeted alpha therapy (TAT) has shown great promise in
the treatment of both micrometastatic [1] and large solid
tumors in preclinical and clinical studies [2, 3]. Alpha-
emitters emit high linear energy transfer (LET) α-particles,
each causing dense ion pairs (2000–7000) within a relative
short path length (50–100 μm) [3]. The radioactive decay of
213bismuth (213Bi, T1/2 = 46 min) results in the emission of
high-LET α-particles by 213Bi self and by its daughter 213Po
around 100 keV/μm. Due to the relative short half-life of
213Bi, 213Bi can deliver a high radiation dose rate to the tar-
get within a relatively short period of time. These physical
characteristics make 213Bi, one of the most commonly used
α-emitters for medical applications, with demonstrated
promise as TAT in preclinical studies, in vivo imaging, and
in clinical treatment of cancer patients [1, 4, 5].
Peptide receptor radionuclide therapy (PRRT) with radi-
olabeled somatostatin analogs is commonly employed in
patients with inoperable neuroendocrine tumors (NETs)
overexpressing somatostatin receptors subtype 2 (SSTR2).
Current radiopeptides include 177Lu-[DOTA0,Tyr3]octreo-
tate (177Lu-DOTATATE) and 90Y-[DOTA0,Tyr3]octreotide
(90Y-DOTATOC). Its efficacy depends on the radiation
absorbed dose delivered to the tumor, which depends on
SSTR2 targeting efficiency, clearance kinetics, perfusion,
distribution, and tumor mass. High-specific activity radio-
peptides are required to deliver adequate radiation
absorbed dose to tumors, as the mass of injected peptide
is limited by the high affinity but low capacity of SSTR2-
expression systems. The mass of injected peptide influ-
ences the pharmacokinetics (PK) and absorbed doses in
organs and tumors [6]. Therefore, the mass of injected
peptide should be optimized to deliver efficacious tumor
doses while avoiding toxic absorbed dose to organs, espe-
cially to the dose-limiting organs the kidneys and bone
marrow [7, 8].
Radiolabeled somatostatin analogs are known to accu-
mulate in the renal proximal tubules, due to their net
charge, electrostatic forces, and charge distribution from
metal-chelation [9, 10]. This can result in a high absorbed
dose and subsequent renal dysfunction. Co-infusion of L-
lysine/L-arginine has been shown to reduce renal uptake
in patients receiving 177Lu-DOTATATE or 177Lu-DOTA-
TOC PRRT by 30–50% [11].
Several preclinical studies showed that TAT with 213Bi re-
sulted in high renal accumulation of radioactivity [12],
causing nephrotoxicity and decreased survival without renal
protection compared to animals receiving protection [13,
14]. Evidence of acute or chronic interstitial nephritis was
found in a previous dose escalation study in AR42J tumor-
bearing rats using 213Bi-DOTATOC [2]. Nephrotoxicity
was observed to be moderate in a clinical trial of 213Bi-
DOTATOC, in combination with renal protection, in pa-
tients’ refractory to 177Lu-DOTATATE or 90Y-DOTATOC
PRRT [3]. Conventional approaches to determine kidney
function use serum creatinine or nuclear medicine imaging
with 99mTc-MAG3 or 99mTc-DSMA. However, these
approaches are suboptimal to detect early-stage kidney
disease. Several renal biomarkers are commercially available
to determine acute or chronic kidney injury [15]. However,
those biomarkers have not yet been applied in PRRT for de-
tection of nephrotoxicity. Neutrophil gelatinase-associated
lipocalin (NGAL) is among the promising renal biomarkers
for detection of acute or chronic kidney injury in humans
with high specificity and sensitivity [16]. Therefore, NGAL
is an interesting renal biomarker to study nephrotoxicity
caused by TAT with 213Bi.
This study aimed to determine the suitability of 213Bi-
DOTATATE for TAT. Administration of 213Bi-DOTA-
TATE was optimized for in vivo applications in AR42J
tumor-bearing mice. The rat AR42J tumor is known to
express SSTR2 at high density; this model is commonly
used for investigations using somatostatin analogs and
PRRT. Additionally, investigations were performed on in-
creasing 213Bi-DOTATATE’s efficacy by using L-lysine as a
renal protectant, radiation dosimetry to determine the
mean radiation absorbed dose to the tumor and kidney,
the resultant dose-effect relation, and a pilot study to
evaluate NGAL as a kidney injury biomarker.
Methods
213Bi-DOTATATE labeling
213Bi was eluted from a 225Ac/213Bi generator (Oak Ridge
National Laboratory) with 0.1 M/0.1 M HCl/NaI. The re-
sultant elution containing 213Bi (630–740 MBq) was used
for labeling with 10 μg DOTATATE (BioSynthema) in a
reaction vial including 0.15 M TRIS buffer and 2.6 mM
ascorbic acid at pH 8.4. The reaction was incubated for
5 min at 95 °C and cooled to ambient temperature for
2 min before adding 50 mM DTPA [17]. Instant thin-layer
chromatography (ITLC-SG, Varian) was performed using
0.9% NaCl as mobile phase to determine the radionuclide-
peptide incorporation yield. High-performance liquid
chromatography (HPLC, Agilent) was performed to deter-
mine the radiochemical purity (RCP) of 213Bi-DOTA-
TATE, being defined as percentage of intact radiopeptide
of interest compared to other detectable radioactive com-
pounds in the same HPLC analysis. HPLC was performed
using a reverse phase C18 column (JT Baker, Bakerbond®,
4.6 × 250 mm) eluted with 0.1% TFA and methanol [18].
111In-DOTATATE labeling
111InCl3 (GE Healthcare) was added to a vial containing
0.03, 0.1, 0.3, 1, or 3 nmol DOTATATE. 115In(NO3)3
(0.01 g/L, ICP standard) was added to form a 1:1 M ratio
reaction to peptide, and NaOAc 4 M was used to adjust the
pH to 4–5. The reaction was heated at 80 °C for 20 min
and cooled to ambient temperature for 5 min before the
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addition of DTPA (50 mM) to incorporate potential free
111In3+. Incorporation yields of the labeled peptide were
evaluated as described previously.
Animal model
Athymic male nu/nu mice (Tachonic), 6–8 weeks old, were
used in all studies. Tumor models were established by
inoculating 5 × 106 rat pancreatic tumor AR42J cells
(American Type Culture Collection) with high SSTR2 ex-
pression into the right hind flank of the animals. After
3 weeks, the tumor size reached approximately 200 mm3.
All animal experiments were carried out following Institu-
tional Animal Care and Use Committee-approved protocol.
Comparison of biodistribution profiles of 111In-DOTATATE
and 213Bi-DOTATATE
AR42J tumor-bearing animals were used for the compari-
son of the uptake of 111In-DOTATATE versus (vs.) 213Bi-
DOTATATE in different organs and tumors. Biodistribu-
tion assays were performed with either 111In-DOTATATE
or 213Bi-DOTATATE (0.3 nmol, n = 3/cohort). Animals
were euthanized 10 and 60 min post-injection (p.i.) by
CO2 asphyxiation. Blood samples were collected, and the
following organs were harvested and counted in a γ-
counter (PerkinElmer): tumor, blood, heart, adrenals,
kidneys, stomach without content, pancreas, liver, testi-
cles, urinary bladder, femur, femur marrow, pituitary, and
muscles. The uptake was expressed as percentage of
injected activity per gram of tissue (%IA/g). The actual
weight of all organs was used to calculate %IA/g.
Biodistribution 111In-DOTATATE
Xenograft AR42J nu/nu mice were used to determine PK
as a function of injected mass of peptide (n = 4/cohort).
Animals were injected intravenously (i.v.) via the tail vein
with 0.03, 0.1, 0.3, 1, or 3 nmol (corresponding to 2 × 10−3,
7 × 10−3, 0.02, 0.07, and 0.22 mg/kg, respectively) of 111In-
DOTATATE (range 0.6–2.9 MBq). Animals were eutha-
nized by CO2 asphyxiation at 3, 10, 30, and 60 min p.i.
Blood samples, organs, and femur-containing femur mar-
row were harvested and counted as described previously.
The uptake was expressed as percentage of injected activ-
ity per gram of tissue (%IA/g).
The effect of L-lysine on the biodistribution of 213
Bi-DOTATATE in tumor and nontumor-bearing mice
Twenty AR42J tumor-bearing mice, 200 mm3 tumor vol-
ume, were injected intraperitoneally (i.p.) with or without
(w/wo) 35 mg/200 μL L-lysine (L-lysine monohydrochloride)
2–10 min prior to 213Bi-DOTATATE administration i.v. (1–
3 MBq/0.3 nmol). Mice were euthanized at 10 and 60 min
p.i. In a parallel study, 20 nontumor-bearing mice were
injected i.p. w/wo L-lysine (35 mg/200 μL) 2–10 min prior
to 213Bi-DOTATATE (1–3 MBq/0.3 nmol) administration
and were euthanized at 10 and 60 min p.i (n = 5/cohort).
Blood, organs, and femur-containing femur marrow were
collected and counted as described previously. The uptake
was expressed as percentage of injected activity per gram of
tissue (%IA/g).
Toxicity and therapeutic efficacy of 213Bi-DOTATATE
Toxicity and therapeutic efficacy were investigated in 18 ani-
mals (n = 6/cohort): control, low-dose (cumulative 16.8 ±
1.3 MBq), and high-dose (cumulative 33.1 ± 3.7 MBq) co-
horts. Treatment started 23 days after xenograft inoculation.
Control mice received in total 4 × 0.3 nmol DOTATATE on
two consecutive days. Two injections of 0.3 nmol DOTA-
TATE per day were given, with a time interval of at least
6 h. The low-dose cohort received two doses of 213Bi-
DOTATATE on two consecutive days, one dose of 8.3 ±
1.0 MBq/0.3 nmol 213Bi-DOTATATE each day. The high-
dose cohort received four doses on two consecutive days,
twice a day with a time interval of at least 6 h. Per dose,
213Bi-DOTATATE contained 8.3 ± 1.0 MBq/0.3 nmol 213Bi-
DOTATATE. Animals were monitored for 30 days starting
on the day of treatment. Tumors were measured by caliper,
and animals were weighed at least twice weekly. The end-
points chosen were weight loss >15% and tumor volume
>2000 mm3. At 30 days post-treatment, blood samples were
obtained for hematological analysis according to the stand-
ard operating procedures for clinical laboratory samples for
creatinine, CBC, WBC, RBC, Hgb, Hct, MCV, MCHC,
platelets, neutrophils, lymphocytes, monocytes, eosinophils,
and basophils. Survival analysis was plotted according to the
Kaplan-Meier fit model.
Tumor volume V(t) as a function of time was modeled ac-
cording to the exponential growth function V(t) =V0 × e
kt,
with k the growth constant, related to the doubling time Td
by k ¼ ln 2ð ÞTd . Each individual mouse V(t) in the control
group was fitted with the exponential growth function to en-
able extrapolation of the growth beyond the time when the
tumor volume exceeded the maximum. An average control
growth curve was obtained by using the mean of the volume
data together with the extrapolated growth data to the time
points of the last surviving animal. Fitting was also per-
formed for the therapy group with an exponential growth
function, where the initial growth rate k0 slowed down or
turned into shrinkage with rate k0− k1 at onset time point
T0 of therapy effect. Regrowth was modeled by exponential
growth with rate k0− k1+ k2, setting in after the volume
nadir time point T1. This led to the function V tð Þ ¼ V 0
ek0t  maxt>T1e−k1t−T1maxt>T2ek2 t−T2ð Þ . The regrowth
doubling time Trd was derived from T rd ¼ ln 2ð Þk0−k1þk2.
Maximum tolerated dose (MTD) of 213Bi-DOTATATE in
nontumor-bearing mice in combination of L-lysine
MTD was defined as the highest dose given to the animals
allowing 100% survival with no significant weight loss >15%
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throughout the experiment. Nontumor-bearing mice were
randomly divided into seven cohorts used to evaluate
MTD, six treatments and one control (n = 8/cohort); see
Table 1. Cohorts(+) received i.p. injections of L-lysine
(35 mg/200 μL) at 2–10 min prior to 213Bi-DOTATATE ad-
ministration via i.v. tail vein. Control mice received DOTA-
TATE (4 × 0.3 nmol) on four consecutive days. The animals
were followed for 90 days. Serum was analyzed for the bio-
marker neutrophil gelatinase-associated lipocalin (NGAL)
using ELISA (R&D Systems, 450 nm). Survival analysis was
plotted according to the Kaplan-Meier fit model.
Pharmacokinetics
Saturation of receptor-specific tumor uptake was investi-
gated by determining the kinetics of the tumor uptake with
increasing injected mass of peptide. The time-activity curves
for the tumor and normal organs were fitted by single-
exponential functions using Prism-5 (GraphPad). Goodness
of fit was analyzed with the Pearson correlation coefficient
R2 > 0.8. Both F test and the Aikake information criterion
were used to decide on the complexity of the curves.
Radiation dosimetry
Cumulated radioactivity in the tumor and normal organs
were estimated by integrating the time-activity curves fitted
to the 111In-DOTATATE biodistribution data and folded
with the decay curve of 213Bi and its daughters. Dosimetry
was performed according to the MIRD schema by using the
spherical nodes S-factors from the Olinda/EXM software
[19]. S-factors were interpolated from the actual weight of
the organs and tissue. All organs and tissue were assumed
to be spherical with a density of 1 kg/m3. Mean radiation
absorbed doses were obtained as a function-injected mass of
peptide, assuming a homogeneous distribution in the tumor
and organs. The mean radiation absorbed dose obtained in-
cluded the cumulative dose of α, β, and γ from all daughters
of 213Bi. Owing to the short path length of α-particles, only
the self-dose within each organ was included. The threshold
for lethality was determined with renal absorbed dose and
injected activity as indicators. Logistic regression analysis
was used to determine the LD50 for presumed renal
toxicity-related death.
Statistics
Data analyses, graphs, and calculations were performed in
Prism-5. Mann-Whitney t test was used to calculate the
significance. The results of statistical tests were considered
significant when P was <0.05. Biodistribution data were
expressed as mean ± standard deviation (SD) and tumor
volume data as mean ± standard error (SEM). Binary
logistic analysis (forced entry method) was performed with
SPSS software (IBM SPSS statistics, version 20).
Results
Radiolabeling
The radiolabeling incorporation yield of 213Bi-DOTA-
TATE was >95% and RCP was >85%; the incorporation
yield of 111In-DOTATATE was >95%.
Biodistribution of 111In-DOTATATE as function of injected
mass of peptide and time
In animals injected with <0.3 nmol 111In-DOTATATE,
higher tumor uptake was observed than in animals
injected with >0.3 nmol, Fig. 1a–f. At lower injected mass
of peptide (0.03, 0.1, and 0.3 nmol), tumor uptake in-
creased as function of time. At >0.3 nmol of injected pep-
tide, the uptake of 111In-DOTATATE was more uniform
and low compared to <0.3 nmol of injected peptide, indi-
cating the receptors on the tumors were partially saturated
by the injected masses of unlabeled peptide. Renal uptake
was higher compared to other organs for all injected mass
of peptide at all time points, except for tumor. Organ up-
take of 0.03–3 nmol mass of injected peptide are indicated
in Additional file 1: Tables S2–S6.
Decreased absorbed tumor doses from 213Bi-DOTA-
TATE as a function of increased of injected mass of pep-
tide was predicted based on the 111In-DOTATATE
uptake data. The mean radiation absorbed tumor dose
ranged between 0.66 Gy/MBq 213Bi-DOTATATE at
0.03 nmol peptide and 0.19 Gy/MBq 213Bi-DOTATATE
at 3 nmol peptide; see Fig. 1f. A comparable mean radi-
ation absorbed dose of 0.50 Gy/MBq was found for 0.1
and 0.3 nmol peptide.
Biodistribution of 111In-DOTATATE vs. 213Bi-DOTATATE
Tumor uptake of 213Bi-DOTATATE compared to 111In-
DOTATATE was 5.3 ± 2.8%IA/g vs. 6.3 ± 1.3%IA/g at
10 min p.i., respectively (P = 0.70). Similar results were
observed at 60 min p.i.: 6.5 ± 2.3%IA/g vs. 6.0 ± 1.2%IA/g,
respectively (P = 1.0).
Renal activity at 60 min p.i. for 213Bi-DOTATATE was
significantly higher than 111In-DOTATATE: 17.4 ± 2.2%IA/
Table 1 213Bi-DOTATATE toxicity study in nontumor-bearing
animals with or without pre-injection of L-lysine (35 mg),
n = 8/cohort
MTD study in nontumor-bearing animals in combination with L-lysine
Cohort 213Bi-DOTATATE (MBq) L-lysine Days of injection
Low-dose(−) 13.0 ± 1.6 − 2
Low-dose(+) 13.2 ± 0.9 + 2
Medium-dose(−) 20.7 ± 0.8 − 3
Medium-dose(+) 21.7 ± 1.9 + 3
High-dose(−) 28.7 ± 1.2 − 4
High-dose(+) 28.3 ± 0.8 + 4
Control 0 4
MTD maximum tolerated dose
Control animals received 4 × 0.3 nmol DOTATATE (n = 8)
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g and 10.9 ± 0.6%IA/g, respectively (P = 0.0022). 111In-
DOTATATE was retained longer in the pancreas at 10 and
60 min p.i., whereas 213Bi-DOTATATE radioactivity in
plasma was higher at 60 min p.i. and uptake in pituitary at
10 and 60 min p.i. All other organs showed similar uptakes
for 111In-DOTATATE and 213Bi-DOTATATE at 10 min
and 60 min p.i.; see Fig. 2.
Biodistribution of 213Bi-DOTATATE; influence of L-lysine
Figure 3 shows the uptake of 213Bi-DOTATATE with or
without L-lysine pre-injection in different organs and tissues
in tumor-bearing and nontumor-bearing animals. Lower
renal uptake was observed in tumor-bearing mice receiving
L-lysine prior to administration of 213Bi-DOTATATE versus
mice without L-lysine (10 min p.i.; 21.3 ± 8.1%IA/g vs. 30.8
± 5.8%IA/g and 60 min p.i.; 5.7 ± 1.1%IA/g vs. 18.4 ±
1.8%IA/g (P <0.0001)).
No differences in tumor uptake were found in animals
w/wo L-lysine pretreatment. However, at 60 min p.i., a sig-
nificant difference in stomach uptake was found in tumor-
bearing animals with and without L-lysine, 0.9 ± 0.1%IA/g
versus 1.6 ± 0.5%IA/g, P = 0.0079. Figure 3 shows the up-
take of 213Bi-DOTATATE w/wo L-lysine pre-injection in
different organs in tumor- and nontumor-bearing animals.
In tumor-bearing animals receiving L-lysine, the renal
absorbed dose was 0.56 Gy/MBq vs. 1.1 Gy/MBq with-
out L-lysine. In nontumor-bearing animals, the renal
absorbed dose was 0.50 Gy/MBq with L-lysine versus
1.0 Gy/MBq without L-lysine; see estimated mean radi-
ation absorbed dose in Additional file 1: Table S7.
Pharmacodynamics of 213Bi-DOTATATE in AR42J tumor-
bearing animals
Tumor volumes significantly decreased in mice treated
with low-dose (16.8 ± 1.3 MBq) and high-dose (33.1 ±
A B
C D
E F
Fig. 1 a–e Tumor uptake (%IA/g) of 111In-DOTATATE as function of time and injected mass of peptide (0.03–3 nmol, n = 4/cohort). The uptake
was expressed as percentage of injected activity per gram of tissue (%IA/g). f Predicted absorbed tumor dose of 213Bi-DOTATATE based on 111
In-DOTATATE tumor biodistribution results. The injected mass of peptide expressed on x-axis and the estimated mean radiation absorbed dose
(Gy) per injected MBq 213Bi-DOTATATE on the y-axis
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3.7 MBq) 213Bi-DOTATATE. Tumor regression was ob-
served in both 213Bi-DOTATATE cohorts. Tumor regrowth
was delayed until 21 ± 9 days p.i. in animals treated with
low-dose 213Bi-DOTATATE; see Fig. 4a. One animal in the
low-dose showed a weight loss of >15% at day 27 post-
treatment. Dramatic weight loss was observed in the high-
dose cohort within 14 days post-treatment, necessitating
euthanasia of 67% of the animals; see Fig. 4b. Therefore,
tumor regrowth doubling time in the high-dose cohort was
not determined. The tumor doubling time in the control
was 4.0 ± 0.2 days, and both the initial growth and regrowth
patterns in the therapy cohorts proceeded with similar
doubling times. A median survival of 5 days was found in
the control, >30 days in the low-dose, and 13 days in the
high-dose; see Fig. 4b. The tumor growth in one animal of
the control cohort showed an unusual growth pattern;
therefore, the data of this animal was excluded from the cal-
culation of the tumor doubling time and survival analysis.
Animals in the high-dose cohort showed significantly
(P = <0.05) elevated hemoglobin (Hgb) and hematocrit
(Hct) values compared to the low-dose (Hgb (g/dL) 51 ± 7
vs. 39 ± 3 and Hct (%) 16 ± 2 vs. 12 ± 1).
MTD in nontumor-bearing mice administration w/wo
L-lysine
Renal protection using L-lysine prior to 213Bi-DOTATATE
administration resulted in prolonged survival for both the
medium-dose(+) (21.7 ± 1.9 MBq) and high-dose(+)
cohorts (28.3 ± 0.8 MBq), Fig. 5. Medium- and high-dose
cohorts without L-lysine showed reduced survival rates
compared to medium- and high-dose cohorts pre-treated
with L-lysine. No animals in high-dose(−) cohort survived
beyond 40 days following treatment. No significant differ-
ence in survival was observed following low-dose adminis-
tration of 213Bi-DOTATATE with or without L-lysine (P =
0.32) or medium-dose with or without L-lysine (P = 0.06).
Weight loss was observed in cohorts treated with
medium-dose(−), high-dose(−), and high-dose(+) cohorts.
At 90 days post-treatment, all control animals survived.
A survival rate of 87.5% was found in the low-dose(−) co-
hort, 62.5% in the medium-dose(−), and 0% in high-
dose(−), Fig. 5a. Cohorts receiving L-lysine pre-treatment,
Fig. 5b, a very high survival rate was observed: 100% in
the low-dose(+) and 100% in the medium-dose(+). In the
high-dose(+) cohort, 75% of the animals survived. A me-
dian survival of >90 days was found in control and all co-
horts except the high-dose without L-lysine (median
survival of 24 days, P = 0.0012).
By integrating the radioactivity over time in the kidney,
data obtained from biodistribution study w/wo pre-
treatment of L-lysine, a time-integrated activity coefficient
(expressed as min/g tissue) of 6.0 ± 2.4 min/g in mice pre-
treated with L-lysine and 12.0 ± 3.7 min/g in mice without
pre-treatment of L-lysine was found. Based on logistic re-
gression analysis, a LD50 of 20 ± 8 Gy was found; see Fig. 6.
The number of mice that were euthanized within 90 days
was indicated as a function of renal absorbed dose ob-
tained from both biodistribution studies w/wo L-lysine.
The highest NGAL level was found in the high-dose(−)
cohort, 15.8 ± 3.5 ng/mL. Whereas the NGAL level of con-
trol, low-dose cohort w/wo L-lysine was the lowest, 1.9 ± 0.9,
1.9 ± 0.6, and 1.7 ± 0.7 ng/mL, respectively. A significant
Fig. 2 Comparative biodistributions (%IA/g ± SD) after i.v. administration of 213Bi-DOTATATE vs. 111In-DOTATATE (0.3 nmol peptide, n = 3/cohort)
at 10 and 60 min p.i. in AR42J tumor-bearing mice. The uptake was expressed as percentage of injected activity per gram of tissue (%IA/g)
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difference in NGAL level was found in medium-dose(−),
high-dose(−), and high-dose(+) vs. control; see Fig. 7.
Discussion
In this preclinical study, TAT with 213Bi-DOTATATE was
systematically studied to understand the injected mass of
peptide-dependent uptake, radioactivity-related toxicity,
and reduction in tumor burden. 111In had already been
used as a surrogate for 213Bi earlier in other preclinical
studies [20, 21]. We demonstrated 111In is an appropriate
surrogate radionuclide for in vivo preclinical studies of PK
in tumors allowing the results obtained from 111In to be
used for 213Bi-dosimetry calculation. Both 213Bi and 111In
form highly stable complexes with DOTA-somatostatin
analogs, including DOTATATE, and show similar affinities
for SSTR2 in tumor.
For PRRT, it is essential to determine the optimal injected
mass of radioligand by defining PK of radiopeptides in
animal models, given that the injected mass of radioligand
influences tumor uptake, the resultant radiation absorbed
dose, and eventually the efficacy of the therapy. Moreover,
increasing the injected mass of radioligand can diminish
the pharmacological selectivity by binding to other SSTR-
positive organs [22], which is not beneficial in the case of
TAT and may cause off-target toxicities. The optimal
injected mass of 111In-OctreoScan® to obtain the best signal
to background ratio for tumor versus other organs was re-
ported as 0.07 nmol in mice (3.5 pmol/g mice) [23]. De
Jong et al. showed a “bell-shape” curve for dependent
tumor uptake in AR42J tumor-bearing rats as a function of
injected mass of peptide, where 0.4 nmol 111In-DOTATOC
(1.8 pmol/g rat) gave the maximum tumor uptake [24].
In this study, the highest absorbed tumor dose
(0.66 Gy/MBq) was found at injected mass of peptide of
0.03 nmol (1.07 pmol/g mice). However, lower and more
practical specific activity (MBq/nmol) 213Bi-DOTATATE,
A B
C D
Fig. 3 Biodistribution comparison of 213Bi-DOTATATE (0.3 nmol) with (w) or without (wo) L-lysine (35 mg) pre-injection. a AR42J tumor-bearing
animals 10 min p.i. b AR42J tumor-bearing animals 60 min p.i. c Nontumor-bearing animals 10 min p.i. d Nontumor-bearing animals 60 min p.i.,
n = 5. The uptake was expressed as percentage of injected activity per gram of tissue (%IA/g)
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0.3 nmol (10.7 pmol/g mice) was chosen for the admin-
istration in this study allowing sufficient tumor uptake
to realize therapeutic effects. A similar mean radiation
absorbed dose of 213Bi-DOTATATE was determined for
0.1 and 0.3 nmol injected mass of peptide, as the tumor
uptakes as function of time of both 0.1 and 0.3 nmol
peptide were similar.
111In-DOTATATE is not an appropriate surrogate of
213Bi-DOTATATE to determine renal uptake as a signifi-
cant difference was observed at 60 min p.i. between 111In-
DOTATATE and 213Bi-DOTATATE. With an absence of
SSTR2 receptors in the kidney, the high renal uptake is not
related to SSTR expression. The renal uptake of the labeled
peptide is thought to be influenced by the difference in the
electrostatic charge of DOTA complex with 111In and 213Bi
[9, 10, 25], leading to different interactions with megalin or
cubilin [26]. Furthermore, 213Bi3+ is known to bind strongly
to metallothionein in the kidneys [27], which might lead to
a high renal uptake. Apart from high renal uptake, a signifi-
cantly higher uptake was also found in the pituitary and a
higher radioactivity level in plasma. The pituitary gland is a
very small organ. During organ harvesting, a systematic
uncertainty is introduced by the chance to include
surrounding tissue in the weight used for the uptake per
gram calculation, resulting to an under- or overestimation
of pituitary uptake, which might explain our findings. The
high renal uptake and slow clearance rate of 213Bi-DOTA-
TATE indicates tubular reabsorption of 213Bi-DOTATATE;
this might be the cause of higher radioactivity in plasma as
well. 111In-DOTATATE showed a slightly significantly
higher uptake than 213Bi-DOTATATE in pancreas tissue, as
yet we do not have an explanation for this difference.
In this study, we were not able to examine the differ-
ences in PKs of these radiopharmaceuticals in pituitary,
A B
Fig. 4 a Tumor growth in mice before and after injection of DOTATATE in control animals (4 × 0.3 nmol DOTATATE) and 213Bi-DOTATATE at
different concentration, in low-dose cohort (16.8 ± 1.3 MBq) and high-dose cohort (33.1 ± 3.7 MBq). Treatment started 23 days after inoculation of
AR42J cells. The solid line indicates the extrapolated fit calculated for tumor growth, and dotted lines indicate the 95% confidence interval for the
fit. b Survival of AR42J-bearing animals after 213Bi-DOTATATE therapy. Low-dose animals received 16.8 ± 1.3 MBq 213Bi-DOTATATE, high-dose 33.1
± 3.7 MBq, and control 4 × 0.3 nmol DOTATATE on 2 consecutive days
A B
Fig. 5 a, b Survival percentage after 213Bi-DOTATATE therapy without (−) or with (+) L-lysine (35 mg) pre-injection in nontumor-bearing mice;
cohort low-dose(−) received cumulatively 13.0 ± 1.6 MBq, low-dose(+) 13.2 ± 0.9 MBq, medium-dose(−) 20.7 ± 0.8 MBq, medium-dose(+) 21.7 ±
1.9 MBq, high-dose(−) 28.7 ± 1.2 MBq, and high-dose(+) 28.3 ± 0.8 MBq (n = 8/cohort). Control animals received 4 × 0.3 nmol DOTATATE (n = 8)
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plasma, and plasma, due to the small number of animal
per group and limited time points.
Despite the differences in PK profiles of 111In-DOTA-
TATE and 213Bi-DOTATATE in some organs and tissues,
111In-DOTATATE still showed to be a proper substitute
for tumor uptake, since the PK profile of the tumor uptake
was similar to that of 213Bi-DOTATATE. However, the use
of a surrogate radionuclide should be carefully chosen,
since each alternate radionuclide has limitations.
Weight loss in animals is often an indicator of toxicity,
and the most radiosensitive organs for PRRT are the
bone marrow and kidney [8, 28, 29]. In this study, we
observed severe weight loss in 67% of animals exposed
to high-dose 213Bi-DOTATATE (cumulative 33.1 ±
3.7 MBq), within 2 weeks after treatment, indicating
acute toxicity. This might be explained by the high renal
uptake resulting in a high renal absorbed dose, which in-
creased the risk of acute nephrotoxicity due to limited
sublethal damage tissue repair. To investigate acute renal
toxicity, a short-term toxicity study over 90 days was
performed instead of a follow-up period over 6–
12 months, which is commonly performed to investigate
long-term chronic nephrotoxicity. A significant reduc-
tion of renal activity (50%) was found in animals pre-
treated with L-lysine in this study. Our findings indicate
that pre-treatment with L-lysine improved survival of an-
imals receiving medium- and high-dose 213Bi-DOTA-
TATE resulting from the reduction of renal activity.
Song et al. showed in their study a threefold reduction
in renal activity following lysine pre-treatment [13]. This
result differs significantly from our findings but might
be attributed to their method of lysine application used
during the therapy procedures, rather than immediately
prior. Kobayashi et al. demonstrated that the kidney up-
take was influenced by the timing of L-lysine administra-
tion [30], such that renal blocking by L-lysine was
maximized when i.p. administration of L-lysine was given
immediately before administration of the radiolabeled of
anti-Tac murine MoAb fragment. In our study, we have
chosen to start the therapy 2–10 min after i.p. adminis-
tration of L-lysine to protect the kidneys, since DOTA-
TATE is a relative small molecule and rapidly cleared
from the blood. Radioactivity in the blood or uptake of
the bone marrow is generally used as an indicator for
myelotoxicity. Pre-administration of L-lysine did not sig-
nificantly affect the radioactivity measured in neither
whole blood nor femur uptake in tumor-bearing mice.
The mean radiation absorbed dose for whole blood and
femur (see Additional file 1) was 3.3 and 1.3 Gy in mice
with pre-treatment of L-lysine in the high-dose cohort,
whereas without L-lysine, these values were 2.7 and
1.0 Gy. These absorbed doses were lower than the MTD
of 25 MBq 213Bi-DOTA-AMBA in PC3-tumor-bearing
mice, corresponding to the MTD at a mean absorbed
dose of 4 Gy in the blood [31]. Therefore, we concluded
the bone marrow is not a limiting organ in our study.
The LD50 found for the renal absorbed dose was 20 Gy in
this study. Acute renal toxicity at 100–140 Gy was reported
by Behr et al., after administration of 90Y-fab fragments,
leading to death of all mice within 2–3 weeks [32]. This cor-
responds to our observation in cohorts after high-dose
213Bi-DOTATATE administration, with more than 90% of
the animals dead at radiation absorbed dose >28 Gy. Hence,
Fig. 6 Dose-effect relation between mean renal radiation absorbed
dose and the percentage of mice that died before the end of the
experiment at 90 days. LD50 kidney dose was 20 ± 8 Gy, a threshold
LD5 = 11 ± 4 Gy (P = <0.001). All points represent at least three mice
Fig. 7 NGAL (ng/mL ± SEM) level in control and 213Bi-DOTATATE-
treated cohorts with (+) or without (−) pre-treatment of L-lysine
(35 mg). Cohort low-dose(−) received cumulatively 13.0 ± 1.6 MBq,
low-dose(+) 13.2 ± 0.9 MBq, medium-dose(−) 20.7 ± 0.8 MBq,
medium-dose(+) 21.7 ± 1.9 MBq, high-dose(−) 28.7 ± 1.2 MBq, and
high-dose(+) 28.3 ± 0.8 MBq. Control animals received 4 × 0.3 nmol
DOTATATE. **P value <0.01 and *** P value <0.001 versus
control values
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the relative biological effect (RBE) was 4–5 for acute renal
toxicity, leading to death within 2–3 weeks, when compar-
ing the absorbed doses in both studies. This estimate for
the RBE for 213Bi-DOTATATE appears to be comparable to
the RBE value of 4 used for delayed renal toxicity by Song
et al. [13]. Specific uptake in functional units of the kidney
might cause changes in radiation absorbed doses to
radiation-sensitive structures like the glomeruli that could
result in less damage than predicted from whole-organ radi-
ation dosimetry. Small-scale micro-dosimetry using the
sub-organ model of Hobbs et al. [33] indicates a possible
lowering of the absorbed dose to the glomeruli when 213Bi
is taken up in the proximal tubules by 44% in comparison
to homogeneous uptake in the mouse cortex assuming
equal kinetics. We found no indication for this sparing
effect; otherwise, the RBE would be in the order of 6–8. A
direct comparative study would be needed to determine
both the RBE and the PK of 213Bi- and 90Y- or 177Lu-labeled
peptides inside the kidneys and its functional units.
In this pilot study, NGAL was used as a biomarker to
evaluate late-stage renal changes after therapy. NGAL is
sensitive to acute kidney injury (AKI) for detection of renal
functions in early nephrotoxicity state [16, 34]. No nephro-
toxicity was found in the low-dose(−) and low-dose(+) co-
horts, corresponding to another study done using similar
injected mass of radioactivity (MBq) 213Bi-DOTATATE as
TAT in nude mice in two different tumor models wherein
nephrotoxicity was investigated by 99mTc-DMSA as a kid-
ney marker [35]. Overall, NGAL levels were lower in mice
pre-treated with L-lysine than mice without pre-treatment
at similar dose of 213Bi-DOTATATE. However, no signifi-
cant difference was found between those cohorts, which
might be explained since NGAL was measured day 90 after
TAT, whereby some repair and recovery of the kidney
might already occur. Furthermore, the mean renal absorbed
dose for the medium-dose(−) and the high-dose(+) cohorts
was 23 and 16 Gy, respectively. These absorbed doses were
similar to the calculated renal LD50, at which 50% of the
treated animals would develop acute nephrotoxicity. The
sigmoid dose-effect curve for renal toxicity (Fig. 6) shows a
steep slope, contributing to a great variation in NGAL
values observed at absorbed doses just above and below the
LD50 value. In this study, NGAL proved to be a valuable
tool to examine AKI for TAT using 213Bi as radionuclide
supporting its use in future investigations of nephrotoxicity
caused by 213Bi. The use of NGAL as a biomarker of
nephrotoxicity is feasible and cost-effective compared to
conventional approaches to determine renal functionality in
preclinical studies. Creatinine, the most commonly used
parameter to determine kidney injury, lacks the ability to
evaluate kidney injury at early stages following PRRT.
99mTc-MAG3 and 99mTc-DMSA for preclinical applications
are invasive, by the use of high radioactivity for imaging,
and require additional data extraction and analysis. In
addition to NGAL, kidney injury molecule-1 (KIM-1) and
cystatine-C are promising biomarkers for both acute and
chronic kidney disease [15]. The ability to study early and
late kidney injury is essential in TAT, using a combination
of both conventional methods, and these commercially
available biomarkers could provide more information lead-
ing to more understanding of the underlying mechanisms
involved in kidney injury after TAT.
Conclusions
213Bi-DOTATATE showed therapeutic effects to reduce
tumor size and prolong survival. Potential nephrotoxicity
caused by 213Bi-DOTATATE was overcome by pre-
treatment with L-lysine. 213Bi-DOTATATE with L-lysine
pre-treatment shows promise as TAT of SSTR2-express-
ing tumors. The biomarker NGAL offers a new approach
to study nephrotoxicity following TAT.
Additional file
Additional file 1: Improved safety and efficacy of 213Bi-DOTATATE
targeted alpha therapy of somatostatin receptor-expressing neuroendrocrine
tumors in mice pre-treated with L-lysine. (DOCX 31 kb)
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